Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi s sarcoma

Size: px
Start display at page:

Download "Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi s sarcoma"

Transcription

1 REVIEW Pegylted liposoml doxorubicin in the tretment of AIDS-relted Kposi s srcom Ashish Udhrin 1 Keith M Skubitz 2 Donld W Northfelt 3 1 Deprtment of Medicine, Myo Clinic Arizon, AZ, USA; 2 Division of Hemtology, Oncology, nd Trnsplnttion, University of Minnesot, MN, USA; 3 Division of Hemtology Medicl Oncology, Myo Clinic Arizon, AZ, USA Abstrct: Kposi s srcom is vsculr tumor of skin nd viscer first described in Prior to the 1980s, this disese ws rrely seen in the Western world, but ws quite prevlent in Sub-Shrn Africn countries. Since the onset of the HIV pndemic in the 1980s, the incidence of Kposi s srcom hs incresed mrkedly in Afric nd continues to be significnt problem in ssocition with AIDS in Western countries. Mny therpies hve been demonstrted to be effective in the tretment of HIV-relted Kposi s srcom, including litretinoin gel, interferon lph, nd vrious forms of cytotoxic chemotherpy. Antiretrovirl therpy combined with cytotoxic gents hs yielded significntly greter efficcy thn chemotherpy lone. However, s reviewed in this report, pegylted liposoml doxorubicin hs been estblished s the tretment of choice for ptients with AIDS-ssocited Kposi s srcom in Western countries. Compelling preclinicl nd clinicl evidence, reviewed herein, hs demonstrted tht the nnoprticle (pegylted liposome) delivery system of this formultion leds to greter tumor locliztion of doxorubicin nd consequent improved efficcy, s well s reduced toxicity. Keywords: liposoml doxorubicin, pegylted liposoml doxorubicin, Kposi s srcom, liposoml dunorubicin, liposoml nthrcyclinces Correspondence: Donld W Northfelt Division of Hemtology Medicl Oncology, Myo Clinic Arizon, AZ, USA Tel Fx Emil northfelt.donld@myo.edu Introduction Kposi s srcom (KS) is the most common mlignncy seen in ptients with humn immunodeficiency virus infection, occsionlly s the initil mnifesttion cquired immunodeficiency syndrome (AIDS) (Wng et l 1995). Prior to the AIDS epidemic, KS ws uncommon, occurring primrily in men in Afric, the Mediterrnen re, or Estern Europe (Mitsuysu 2000). Although it ws n exceedingly common compliction of AIDS in western countries in the 1980s t the onset of the epidemic, in the 1990s the incidence of AIDS-relted KS (AIDS-KS) in developed countries decresed drmticlly; between 1990 nd 1997, tht decline ws 10% per yer. An dditionl decline in the incidence of AIDS-KS occurred in ssocition with widespred implementtion of highly ctive ntiretrovirl therpy (HAART) in the lte 1990s. Also, it hs been speculted tht sfer sexul prctices mong homosexul men my hve led to reduced trnsmission of humn herpesvirus-8 (HHV-8), the virus ssocited with ll forms of KS, nd tht the introduction of more effective ntiretrovirl tretments with ssocited reduction in immunodeficiency my lso hve resulted in more effective immune response to HHV-8. Any or ll of these fctors could ccount for the observed decline in incidence of AIDS-KS over the course of the epidemic. Nevertheless, AIDS-KS continues to be dignosed mong HIV-infected persons. Control of HIV infection is not uniformly chieved with HAART, either becuse of drug resistnce nd/or s result of poor dherence to prescribed drug regimens. Additionlly, some ptients continue to develop AIDS-KS despite effective HIV suppression. Furthermore, rtes of AIDS-KS continue to rise in prts of Afric where rtes of both HIV nd HHV-8 infection re high nd HIV tretment is not widely vilble. Interntionl Journl of Nnomedicine 2007:2(3) Dove Medicl Press Limited. All rights reserved 345

2 Udhrin et l Clinicl presenttion of AID-KS AIDS-KS is multifocl, systemic disese tht usully first ppers s pink, red, purple, or brownish-blck nodules, mcules, ptches, or plques on the skin or, less often, on the orl mucos (Wng et l 1995). In the setting of HIV infection, AIDS-KS lesions often occur on the upper body, especilly the hed nd neck. Disese confined to the lower extremities is more common in non-hiv-ssocited KS (Misuysu 2000). Orl lesions hve reportedly ccounted for 22% of the sites of initil presenttion in AIDS-KS. Lesions of AIDS-KS my develop in the lungs, gstrointestinl trct, nd lymph nodes nd hve lso been described in the gllbldder, on the mucos of the vocl cords nd conjunctiv, genitli, liver, spleen, hert, bone, thyroid glnd, nd/or bone mrrow (Wng et l 1995). Depending on their loction nd size, AIDS-KS lesions my be disfiguring nd cn cuse edem, pin, gstrointestinl bleeding, nd tooth loss, nd cn led to nutritionl deficiencies nd disfigurement with consequent socil isoltion. Moreover, lesions in criticl sites cn interfere with eting, speking, brething, nd sometimes produce ftl consequences (Peters et l 1991; Wng et l 1995). The course of the disese vries from development of single or few indolent lesions with miniml progression over time, to ggressive, debilitting, widespred disese with severe complictions emerging within short time (Wng et l 1995; Krown 2004). Rtionle for use of liposoml nthrcyclines in tretment of AIDS-KS Severl liposoml nthrcycline products hve been investigted for the tretment of AIDS-KS. In prticulr, polyethylene glycol-coted ( pegylted ) liposoml product with trde nmes Doxil or Celyx (doxorubicin HCl liposome injection [PLD]; the former distributed in the US by Tibotec Therpeutics, Division of Ortho Biotech Products, LP, Bridgewter, NJ; the ltter distributed outside the US by Schering-Plough Corp.), received ccelerted pprovl from the United Sttes Food nd Drug Administrtion (US FDA) in November 1995 for tretment of ptients with AIDS-KS whose disese either hd progressed on prior combintion chemotherpy or who were intolernt of such therpy (Doxil 2001). In April 1996, the non-pegylted liposoml product, DunoXome (DNX, dunorubicin citrte liposome; Giled Sciences, Foster City, CA) ws pproved s tretment of AIDS-KS for which no prior chemotherpy hd been dministered ( first-line tretment) (DunoXome 1996). Results of phse II tril in AIDS-KS ptients were lso reported for non-pegylted formultion of liposoml doxorubicin, Myocet (liposome-encpsulted doxorubicin citrte complex; Medeus Phrm, Stevenge, Herts UK) (Cheung et l 1999), but this gent is not pproved for tretment of AIDS-KS in the US. Encpsultion of conventionl doxorubicin within liposomes ws expected to preferentilly distribute drug into tumors with leky blood vessels, condition which it ws believed would fcilitte the extrvstion of liposomes into tumor strom (Allen nd Mrtin 2004). Becuse AIDS-KS lesions contin dilted vsculr spces filled with extrvsted erythrocytes, good drug uptke due to similr extrvstion of liposomes ws nticipted. Pegyltion of liposomes ws expected to offer dvntge over conventionl liposomes by preventing erly clernce of circulting liposomes by mcrophges of the reticuloendothelil system. This would theoreticlly led to longer circultion time for the liposomes nd thereby enhnce their opportunity to trverse tumor vsculture where extrvstion could occur. In vitro studies demonstrted the ntitumor ctivity of conventionl doxorubicin in KS-derived cell cultures (Logn et l 1991). Other in vitro studies showed tht exposure to PLD inhibited the prolifertion of KS-derived cells to greter extent thn the prolifertion of endothelil cells, monocytes, nd smooth muscle cells (Sturzl et l 1994). It ws lso shown tht PLD incresed the expression of monocyte chemottrctnt protein-1 in KS cells, substnce believed to led to incresed migrtion of monocytes into the tumor (Sturzl et l 1994). Before initition of clinicl studies, it ws shown in niml models of KS tht PLD ws preferentilly tken up into tumor tissue (Hung et l 1993). Using model of KS derml lesions in trnsgenic mice bering the HIV tt gene (Vogel et l 1998; Hung et l 1993), pegylted liposomes were shown to extrvste into the interstitil spces between spindle-shped KS cells. Liposomes were found predominntly within the lesion in the region djcent to the epidermis, with dense concentrtions round bnorml blood vessels. In ddition, electron microscopy showed tht some mcrophges nd spindle cells hd ingested intct liposomes. Skin biopsies of ptients under tretment with PLD provided dditionl evidence for the preferentil tumor uptke observed in niml models (Vil et l 2004). When encpsulted in pegylted liposome, doxorubicin concentrtions in KS lesions reched times those in norml skin (Northfelt et l 1995). In ddition, it ws shown tht more doxorubicin ws delivered to AIDS-KS lesions when dministered s PLD thn s conventionl doxorubicin. Kposi s lesions from 18 ptients were biopsied 72 hours fter intrvenous injection of either PLD 346 Interntionl Journl of Nnomedicine 2007:2(3)

3 Pegylted liposoml doxorubicin for Kposi s srcom or conventionl doxorubicin (Northfelt et l 1996). Regrdless of the dose, tissue levels of doxorubicin were pproximtely 5 11 times higher in the AIDS-KS lesions of ptients treted with PLD compred with AIDS-KS lesions in ptients given comprble doses of conventionl doxorubicin. Efficcy of liposoml nthrcyclines in clinicl trils of tretment for AIDS-KS Results of phse I/II trils of PLD in reltively unselected cohorts of ptients with AIDS-KS demonstrted overll response rtes (complete nd prtil response [CR + PR]) rnging from 38% to 100% (Sturzl et l 1994; Hengge et l 1993, 2001; Simpson et l 1993; Bogner et l 1994; Jmes et l 1994; Wgner et l 1994; Bergin et l 1995; Hrrison et l 1995; Goebel et l 1996; Northfelt et l 1997; Grunug et l 1998; Newell et l 1998; Nuncez et l 2001). To illustrte these findings we will focus on the tril reported by Northfelt et l (1997) (Tble 1), which provided the dt tht led to initil pprovl of PLD by the United Sttes Food nd Drug Administrtion (US FDA). It ws limited to ptients who hd experienced disese progression or intolerble toxicities during tretment with the combintion of doxorubicin, bleomycin, nd vincristine (ABV) or the combintion of bleomycin nd vincristine (BV) chemotherpy. The 53 ptients enrolled in this tril received 20 mg/m 2 of PLD intrvenously once every 3 weeks; 19 ptients (36%) chieved PRs nd one chieved complete clinicl response. Among those who hd previously experienced disese progression when receiving Tble 1 Effi ccy of pegylted-liposoml doxorubicin in the tretment of AIDS-relted Kposi s srcom fter filure of stndrd chemotherpy (Northfelt et l 1997) Best response All ptients Doxorubicin (n = 53) filure (n = 28) Complete clinicl 1 (2%) 0 Prtil 19 (36%) 9 (32%) Stble 19 (36%) 14 (50%) Progression 14 (26%) 5 (18%) Medin time (dys) to PR Medin durtion (dys) of PR Medin time (dys) to tretment Filure Ptients whose AIDS-KS progressed on combintion regimen contining doxorubicin. conventionl doxorubicin-contining regimen (eg, ABV rther thn BV), the PR rte ws 32%. Medin durtion of response nd time to tretment filure in ll ptients ws 128 nd 134 dys, respectively. Of the 53 ptients, 48 hd rised indictor lesions t bseline; complete flttening of these lesions occurred in 48% of these ptients nd 68% chieved prtil or complete responses. Forty-eight of the ptients hd red or purple indictor lesions t bseline; in 56% of these ptients the lesions chnged to less noticeble color, nd 82% of these ptients chieved prtil or complete responses. Among the 23 ptients with edem t study entry, study therpy reduced edem in 83%, nd 100% of those chieved PR or CR. Of the 22 ptients with pin t bseline, 45% (70% of whom ttined PR or CR) hd pin reduction. These pprent benefits of PLD did not result in PR or CR in some ptients becuse they filed to fulfill some other qulifiction for response, such s no progression t other sites. Although not ddressed specificlly in the study described bove, other observtions demonstrted tht PLD could be effective in relieving symptoms nd possibly prolonging survivl of ptients with pulmonry AIDS-KS. In retrospective nlysis of 20 ptients, including nine who hd received prior chemotherpy, 11 of 16 ptients whose tumors could be evluted hd improved findings on chest rdiogrphy, nd the verge rteril prtil pressure of oxygen (po 2 ) for ll ptients rose to 76 from 55.5 mmhg (p < 0.01). Dyspne nd/or cough resolved in 12 of 16 ptients who hd been symptomtic before tretment (Grunug et l 1998). The evidence supporting the use of PLD lone s first-line therpy is derived from two rndomized trils in which ptients on the control rm received either ABV or BV (Tble 2) (Stewrt et l 1998; Northfelt et l 1998). In the tril conducted by Stewrt et l (1998) 241 ptients who hd received no prior cytotoxic chemotherpy were rndomized to receive either PLD 20 mg/m 2 or BV (bleomycin 15 mg/m 2 nd vincristine 1.4 mg/m 2 ). Both regimens were dministered intrvenously every 3 weeks for six cycles. Overll best response (CR plus PR) ws significntly higher with PLD (58.7% vs 23.3%; p < 0.001), s ws end-of-tretment response (38.8% vs 14.2%; p < 0.001). The end-of-tretment response reflected the ptient s sttus t the time further therpy ws discontinued; the response designtion ws scored within 21 dys of the lst dose of therpy nd must hve been sustined for t lest 4 weeks. The verge time to response ws 49 dys with PLD vs 57 dys with BV. The men durtion of response ws similr for the groups (160 dys with PLD vs 157 dys with BV). PLD produced significntly greter improvements in lesion thickness, nodulrity, edem, color, Interntionl Journl of Nnomedicine 2007:2(3) 347

4 Udhrin et l Tble 2 Response rtes in rndomized trils compring liposoml nthrcycline with ABV or BV, b Stewrt et l 1998 Northfelt et l 1998 PLD (Doxil) BV P vlue PLD (Doxil) ABV P vlue (n = 121) (n = 120) (n = 133) (n = 125) CR, % 6 1 < NS PR, % < <0.001 CR + PR, % (95% CI) 59 (50 67) 23 (16 31) 46 (37 54) 25 (17 32) Stble disese, % Progressive disese, % Not ssessble, % Best response during tretment. b Prtil response defi ned s bsence of new cutneous or orl lesions, new viscerl sites of involvement, or the ppernce or worsening or tumor-ssocited edem or effusions plus t lest one of the following: 50% decrese in the sum of the products of the skin lesions, complete fl ttening of greter thn 50% of ll previously rised skin lesions, 50% decrese in the sum of the products of the lrgest perpendiculr dimeters of prospectively selected indictor skin lesions, or the ptient met the criteri for Complete Clinicl Response, except tht residul tumor-ssocited edem or effusion ws present. The response ws required to persist for t lest 4 weeks. Abbrevitions: ABV, doxorubicin, bleomycin, vincristine; BV, bleomycin, vincristine; CR, complete response; PR, prtil response; NS, not signifi cnt. pin, nd size thn did BV. Among those treted with PLD, the incidence of pulmonry symptoms (dyspne, cough, chest pin, or effusion) dropped from 23.1% to 10.6% (p = 0.002), while for those on the BV regimen, pulmonry symptoms decresed from 24.4% to 20.2% (p = 0.25). The incidence of gstrointestinl symptoms relted to AIDS-KS (bleeding, erly stiety, or dysphgi) decresed from 16.3% t bseline to 3.8% with PLD tretment (p < 0.001), nd from 17% to 9.4% (p = 0.06) with BV tretment. Mortlity ws similr in the two groups: 15.7% with PLD vs 14.2% with BV, with men time to deth of 239 dys versus 160 dys, respectively. Only three of the deths were cused by KS nd none ws ttributed to the tretments studied. This study, s well s most of the others trils described here, ws conducted before the introduction of HAART. Becuse survivl of AIDS-KS ptients is determined primrily by opportunistic infections nd other non-ks complictions of AIDS, the durtions of survivl in these studies is shorter thn might be expected tody with vilbility of more effective tretment of the underlying disese. In the second rndomized tril of first-line therpy with PLD for AIDS-KS (Northfelt et l 1998), lso performed before the introduction of HAART, 258 ptients with no prior chemotherpy were rndomized to receive either PLD (20 mg/m 2 ) or ABV (conventionl doxorubicin 20 mg/m 2, bleomycin 10 mg/m 2, nd vincristine 1 mg), dministered every 2 weeks. The overll response ws significntly better with PLD thn with ABV (45.9% vs 24.8%; p < 0.001) (Tble 2). The time to response ws gin shorter with PLD (medin, 39 dys vs 50 dys with ABV; p = 0.014). Compred with PLD, more thn three times s mny ptients discontinued ABV becuse of n dverse event (37% vs 11%). PLD-treted ptients remined on tretment longer either becuse it ws well tolerted or becuse they responded to tretment. More rpid dropout of ptients in the ABV tretment group might hve influenced cumultive response rtes, but the study did not exmine this possibility. Significnt differences between the tretments fvored PLD in the frequency with which lesions decresed in size, indictor lesions flttened, lesion color returned closer to tht of norml skin, pulmonry dysfunction improved, pin decresed, hed nd limb mobility improved, exercise tolernce incresed, sleep disturbnces decresed, nd sense of socil wellbeing incresed. The tretments showed no significnt differences in reduction of lesion edem or pin, or ptients bility to wlk or wer clothing more esily. Neither the medin durtion of response (PLD, 90 dys; ABV, 92 dys; p = 0.234) nor the medin overll survivl (both groups, 160 dys differed between tretment groups. Ptients enrolled in the tril compring PLD with ABV (Northfelt et l 1998) were sked to complete 30-item AIDS-relted helth-relted qulity of life questionnire before tretment (bseline), every 2 weeks during tretment, nd pproximtely 21 dys post-tretment (Osob et l 2002). Twenty-two items were ssessed within 9 domins: generl helth, pin, socil functioning, nd overll qulity of life (1 item ech); mentl helth (5 items); energy/ftigue (4 items); helth distress (4 items); nd cognitive functioning (4 items). Scores t bseline nd end of tretment were trnsformed to scle from 0 to 100, with higher scores indicting better helth. In ech of the domins there ws n improvement in helth-relted qulity of life ssocited with PLD tretment, nd six of these nine chnges were sttisticlly significnt (Tble 3) (Osob et l 2001). In contrst, ABV tretment resulted in improved helth-relted qulity of life in only two domins nd in worsened helth-relted qulity of life in three domins, two of which were significntly reduced. 348 Interntionl Journl of Nnomedicine 2007:2(3)

5 Pegylted liposoml doxorubicin for Kposi s srcom Tble 3 Chnges in helth-relted qulity-of-life prmeters in ptients with Kposi s srcom PLD (Doxil) (n = 118) ABV (n = 114) Domin No. of Chnge P No. of Chnge P P vlue ptients from vlue b ptients from vlue b between bseline bseline groups c Generl helth NS Pin NS 0.01 Cognitive functioning NS NS Mentl helth NS NS Overll qulity of life NS NS Socil functioning NS 0.03 Energy/ftigue NS Helth distress < NS NS Helth trnsition NS NS NS Scores t bseline nd end of tretment rnged from 0 to 100, with higher scores nd positive chnges Indicting better helth. b Wilcoxon signed-rnk test compring the chnge from bseline to the end of the tretment within tretments. c Wilcoxon rnk-sum test compring the chnge from bseline to end of tretment between tretments. Abbrevitions: ABV, doxorubicin, bleomycin, vincristine; NS, not signifi cnt. There ws significnt difference between the two tretments in four domins: generl helth, socil functioning, nd energy/ftigue. A cliniclly significnt improvement ws defined s chnge of 10 points or more from bseline in the overll qulity-of-life score, nd more ptients in the PLD group thn the ABV group chieved this endpoint (65% vs 43%, p = ). The durtion of cliniclly significnt improvement in overll qulity of life ws lso longer in the PLD-treted group thn in the ABV group (p = 0.049). To determine whether the ddition of other gents to PLD might led to improved tretment outcome, the AIDS Clinicl Trils Group performed study which rndomized ptients who hd not received prior chemotherpy to receive tretment with PLD (20 mg/m 2 ) either lone or in combintion with BV (bleomycin 10 U/m 2, nd vincristine 1 mg), dministered every 2 weeks (Misuysu et l 1997). Among 126 evluble ptients, overll responses were similr in the two groups: 79% with PLD lone versus 80% when combined with BV. Five ptients in ech group experienced CR. Medin time to tumor progression or deth ws lso similr: 29 nd 32 weeks, respectively. Ptients treted with PLD lone showed trend towrd better survivl t the time of n interim nlysis; with the single-gent, qulity of life decresed less rpidly during tretment. The uthors concluded tht dding BV to PLD offered no dditionl benefit. Sfety of pegylted liposoml doxorubicin in clinicl trils Toxicities observed in phse I/II studies of PLD for KS re shown in Tble 4 (Hengge et l 1993; Bogner et l 1994; Hrrison et l 1995; Goebel et l 1996; Northfelt et l 1997; Grunug et l 1998; Newell et l 1998). Neutropeni ws progressive with succeeding courses of PLD nd ws the most common dose-limiting side effect, with n incidence tht rnged from 28.6% to 85% in vrious trils. This wide vrition ws likely relted to the degree to which AIDS hd compromised the mrrow in ddition to the effects of prior chemotherpy. In these trils, the overll incidences of lopeci nd nuse nd vomiting were low (generlly <20%). In contrst to studies of ptients with solid tumors in which PLD ws dministered t higher dose, the incidences of hnd-foot syndrome (HFS; 0% 2%) nd infusion rections (0% 15%) were reltively low. Infusion rections to PLD were chrcterized by some or ll of the following: flushing, tchycrdi, dyspne, hypertension or hypotension, chest pin, bdominl pin, nd bck pin. Tble 4 Effi ccy of pegylted-liposoml doxorubicin in the tretment of AIDS-relted Kposi s srcom fter filure of stndrd chemotherpy: dverse events (Northfelt et l 1997) Event All events Severe (n = 53) (% ptients) (% ptients) Any dverse event 76% 30% Leukopeni 40% 17% Nuse nd/or vomiting 19% 0% Alopeci 9% 0% Astheni 9% 2% Fever 8% 2% Dirrhe 6% 2% Thrombocytopeni 6% 2% Adverse events occurring in 5% of ptients, thought to be possibly or probbly relted to pegylted-liposoml doxorubicin. Interntionl Journl of Nnomedicine 2007:2(3) 349

6 Udhrin et l A similr sfety profile ws observed in the phse III rndomized comprisons of PLD nd either BV or ABV (Stewrt et l 1998; Northfelt et l 1998). Compred with these combintion regimens, PLD ws ssocited with reduced incidence of nuse/vomiting, lopeci, nd neuropthy (from vincristine, which is used in both the BV nd ABV regimens) (Tble 5). In the tril of PLD vs ABV (Northfelt et l 1998) myelosuppression nd fever were less severe with PLD, but this did not trnslte into reduced incidence of infection. In the comprison with BV (Stewrt et l 1998), PLD ws more myelosuppressive becuse neither bleomycin nor vincristine is ssocited with substntil bone mrrow toxicity. HFS ws uncommon with the PLD doses nd schedules used in these trils. No cses occurred in either group of one tril (Stewrt et l 1998), nd in the other tril, 4% of PLD-treted ptients nd 1% of ABV-treted ptients experienced HFS (Tble 5). Mucositis, stomtitis, nd infusion rections such s dyspne nd hypotension occurred more frequently on the PLD rms; infusion rections tht occurred with BV consisted primrily of fever nd rigors. Comprtive tril: PLD vs DNX PLD ws initilly grnted ccelerted pprovl by the US FDA, when the only dt vilble for regultory review were from uncontrolled trils in ptients with AIDS-KS which ws refrctory to conventionl therpy, or in ptients who were intolernt of conventionl chemotherpy regimens. At the request of the US FDA, double-blind rndomized tril of PLD nd DNX tretment for AIDS-KS ws undertken primrily to confirm erlier dt for PLD, rther thn s comprison between the two drugs (Henry et l 2002). In this tril ptients were rndomized in 3:1 rtio to receive PLD or DNX, respectively. The nture of the tril nd the smll number of ptients enrolled precluded robust sttisticl nlysis, nd p vlues were not clculted. For enrollment ptients were required to hve t lest one KS-relted symptom t bseline so tht clinicl benefit could be ssessed. Ptients were initilly eligible only if they were refrctory to conventionl chemotherpy, but the tril ws ultimtely mended to llow ptients without or with limited prior chemotherpy becuse of slow ccrul to the study. As result, 7 of 80 ptients enrolled hd received prior chemotherpy. Ptients were rndomized to PLD 20 mg/m 2 or DNX 40 mg/m 2 given intrvenously every 2 weeks for up to six cycles. Although sttisticl tests were not performed, differences in clinicl benefit nd tumor response tended to fvor PLD (n = 60) over DNX (n = 19) mong the ptients who received t lest one dose of study tretment (Tble 6). Clinicl benefit ws defined s improvement from bseline in t lest one Tble 5 Incidences (%) of dverse events in rndomized trils compring liposoml nthrcycline with ABV or BV Stewrt et l 1998 Northfelt et l 1998 PLD (Doxil) BV P vlue PLD (Doxil) ABV P vlue (n = 121) (n = 120) (n = 133) (n = 125) Neutropeni grde 3/ < Neutropeni grde Neutropeni grde G-CSF required Fever Sepsis OIs < Orl cndidisis Anemi Thrombocytopeni Alopeci <0.001 Neuropthy ll grdes 3 14 < Constiption 2 11 <0.01 Nuse (ll grdes) Nuse/vomiting grde 3/ <0.001 Stomtitis grde 3/ Infusion rections Skin rsh 12 9 Hnd-foot syndrome 4 1 Includes 2 skin rshes in PLD treted ptients not clled hnd-foot syndrome but totlly consistent with the syndrome. Notes: Unless noted, differences re not sttisticlly signifi cnt. Abbrevitions: ABV, doxorubicin, bleomycin, vincristine; BV, bleomycin, vincristine; G-CSF, grnulocyte colony-stimulting fctor; OI, opportunistic infection. 350 Interntionl Journl of Nnomedicine 2007:2(3)

7 Pegylted liposoml doxorubicin for Kposi s srcom AIDS-KS symptom ctegory tht lsted for 28 dys or longer in the bsence of disese progression or severe drug-induced toxicity. Using this definition, 80% of PLD-treted ptients nd 63% of DNX-treted ptients experienced clinicl benefit. The definition of sustined clinicl benefit ws more restrictive, nd involved improvement in t lest one symptom ctegory for 28 dys or longer with no worsening of other symptom ctegories nd no increse in medicl interventions either before or during tht period. Sustined clinicl benefit ws observed in 37% of PLD-treted ptients nd 16% of DNXtreted ptients. An externl HIV/AIDS expert who ws blinded to tretment lloction determined tht clinicl study photogrphs showed clinicl efficcy rtes of 35% for PLD nd 38% for DNX. Prtil tumor response ws defined s one or more of the following: (1) no new lesions (skin or orl), no new viscerl sites of involvement, no ppernce or worsening of tumorssocited edem or effusions, nd 50% or greter decrese in the number of ll previously existing lesions lsting for t lest 4 weeks; (2) complete flttening of t lest 50% of ll previously rised lesions; (3) 50% decrese in the sum of the products of the lrgest perpendiculr dimeters of the indictor lesions; or (4) the ptient met the criteri for complete clinicl response except residul tumor-ssocited edem or effusion. Using these criteri, 55% of ptients in the PLD group nd 32% of ptients in the DNX group hd PR to liposoml nthrcycline therpy. There ws positive correltion between clinicl benefit nd tumor response (Person correltion coefficient, 0.25; p = 0.028). Ninety-two percent of ptients who responded to PLD experienced clinicl benefit, nd 42% of responders in the PLD group experienced sustined clinicl benefit. There were concerns tht the introduction of HAART, which occurred round the time the study begn to enroll ptients, might hve confounded the results of the study. An dditionl nlysis of the dt thus considered ntiretrovirl therpy to be potentil confounding fctor if it ws begun within 28 dys of study entry or ws chnged during the study. The observed rtes of clinicl benefit were not significntly different between ptients who met these criteri for potentilly confounding tretment nd those who did not (26% nd 35%, respectively; p = 0.461). Differences in the nture nd frequency of side effects from the two drugs were smller thn might hve been expected from indirect comprisons drwn from dt shown in Tbles 6 nd 7. HFS nd infusion rections were seen only with PLD. In ll but one of the ptients who experienced HFS or infusion rections, the rections were grde 1/2, nd none of the rections cused ptients to discontinue tretment. Conclusion Mny new nd interesting gents re under development for treting AIDS-KS, including ngiogenesis inhibitors, loclly pplied nd orl retinoids, more effective nti-retrovirl gents, nd drugs trgeting HHV-8. However, liposoml nthrcyclines re still considered by mny to be the initil drugs of choice for this disese when it is dvnced nd symptomtic. Phse 1 clinicl trils confirmed tht delivery vi pegylted liposomes does concentrte doxorubicin in AIDS-KS lesions more effectively tht does tretment with conventionl doxorubicin, s well s concentrting doxorubicin to greter degree in AIDS-KS lesions thn in djcent norml skin (Northfelt et l 1993, 1995). A number of phse II clinicl trils demonstrted substntil effectiveness nd good tolerbility of PLD in tretment of AIDS-KS, even in ptients who hd previously been treted with conventionl chemotherpy, including conventionl doxorubicin (Sturzl et l 1994; Hengge et l 1993, 2001; Simpson et l 1993; Bogner et l 1994; Jmes et l 1994; Wgner et l 1994; Bergin et l 1995; Hrrison et l 1995; Goebel et l 1996; Northfelt et l 1997; Grunug et l 1998; Newell et l 1998; Nuncez et l 2001). Finlly, in phse III clinicl trils in which PLD compred with conventionl tretment with BV or ABV, PLD ws ssocited with higher response rte, shorter time to response, nd less toxicity in ptients with AIDS-KS (Stewrt et l 1998; Northfelt et l 1998). PLD lso improved severl domins of helth-relted qulity of life compred with ABV (Osob et l 2001). Thus, liposoml nthrcyclines, nd in prticulr PLD, pper to offer comprble or superior efficcy, improved tolerbility, nd improved qulity of life reltive to conventionl chemotherpy for AIDS-KS, vlidting the theoreticl dvntge of pegylted liposoml drug delivery in this disese. References Allen TM, Mrtin FJ Advntges of liposoml delivery systems for nthrcyclines. Semin Oncol, 31(Suppl 13):5 15. Bergin C, O Lery A, McCrery C, et l Tretment of Kposi s srcom with liposoml doxorubicin. Am J Helth Syst Phrm, 52: Bogner JR, Kronwitter U, Rolinski B, et l Liposoml doxorubicin in the tretment of dvnced AIDS-relted Kposi srcom. J Acquir Immune Defi c Syndr, 7: Cheung TW, Remick SC, Azrni N, et l AIDS-relted Kposi s srcom: A phse II study of liposoml doxorubicin. The TLC D-99 Study Group. Clin Cncer Res, 5: DunoXome (dunorubicin citrte liposome injection) prescribing informtion Sn Dims, CA, Giled Sciences, Inc. Doxil (doxorubicin HCl liposome injection) prescribing informtion Bridgewter, NJ, Ortho Biotech Products, LP. Interntionl Journl of Nnomedicine 2007:2(3) 351

8 Udhrin et l Goebel FD, Goldstein D, Goos M, et l Efficcy nd sfety of Stelth liposoml doxorubicin in AIDS-relted Kposi s srcom. The Interntionl SL-DOX Study Group. Br J Cncer, 73: Grunug M, Bogner JR, Loch O, et l Liposoml doxorubicin in pulmonry Kposi s srcom: Improved survivl s compred to ptients without liposoml doxorubicin. Eur J Med Res, 3: Hrrison M, Tomlinson D, Stewrt S Liposoml-entrpped doxorubicin: An ctive gent in AIDS-relted Kposi s srcom. J Clin Oncol, 13: Hengge UR, Brockmeyer NH, Bumnn M, et l Liposoml doxorubicin in AIDS-relted Kposi s srcom. Lncet, 342:497. Hengge UR, Esser S, Rudel HP, et l Long-term chemotherpy of HIV-ssocited Kposi s srcom with liposoml doxorubicin. Eur J Cncer, 37: Henry D, Cooley T, Volberding P, et l Finl results of phse III rndomized tril of Doxil vs DunoXome in ptients with AIDS-relted Kposi s srcom (KS) [bstrct]. Proc Am Soc Clin Oncol, 21:411 (bstr 1640). Hung SK, Mrtin FJ, Jy G, et l Extrvstion nd trnscytosis of liposomes in Kposi s srcom-like derml lesions of trnsgenic mice bering the HIV tt gene. Am J Pthol, 143: Jmes ND, Coker RJ, Tomlinson D, et l Liposoml doxorubicin (Doxil): An effective new tretment for Kposi s srcom in AIDS. Clin Oncol (R Coll Rdiol), 6: Krown SE Highly ctive ntiretrovirl therpy in AIDS-ssocited Kposi s srcom: Implictions for the design of therpeutic trils in ptients with dvnced, symptomtic Kposi s srcom. J Clin Oncol, 22: Logn DM, Filion LG, Gudreult R The effect of dunorubicin (Duno) or doxorubicin (Doxo) on epidemic Kposi s srcom (EKS) derived cell cultures [bstrct]. Int Conf AIDS, 7:99 (bstr WA 1030). Mitsuysu RT AIDS-relted Kposi s srcom: Current tretment options, future trends. Oncology (Williston Prk), 14: Mitsuysu RT, von Roenn J, Krown S, et l Comprison study of liposoml doxorubicin (DOX) lone or with bleomycin nd vincristine (DBV) for tretment of dvnced AIDS-ssocited Kposi s srcom (AIDS-KS): AIDS Clinicl Tril Group (ACTG) protocol 286 [bstrct]. Proc Am Soc Clin Oncol, 16:55 (bstr 191). Newell M, Milliken S, Goldstein D, et l A phse II study of liposoml doxorubicin in the tretment of HIV-relted Kposi s srcom. Aust N Z J Med, 28: Northfelt DW, Dezube BJ, Thommes JA, et l Efficcy of pegylted liposoml doxorubicin in the tretment of AIDS-relted Kposi s srcom fter filure of stndrd chemotherpy. J Clin Oncol, 15: Northfelt DW, Dezube BJ, Thommes JA, et l Pegylted-liposoml doxorubicin versus doxorubicin, bleomycin, nd vincristine in the tretment of AIDS-relted Kposi s srcom: Results of rndomized phse III clinicl tril. J Clin Oncol, 16: Northfelt DW, Kpln L, Russell J, et l Phrmcokinetics nd tumor locliztion of DOX-SL (Stelth liposoml doxorubicin) by comprison with Adrimycin in ptients with AIDS nd Kposi s srcom. In Lsic DD, Mrtin FJ (eds). Stelth liposomes. Boc Rton, FL, USA: CRC Press. p Northfelt DW, Mrtin FJ, Working P, et l Doxorubicin encpsulted in liposomes contining surfce-bound polyethylene glycol: Phrmcokinetics, tumor locliztion, nd sfety in ptients with AIDS-relted Kposi s srcom. J Clin Phrmcol, 36: Nunez M, Sblls P, Vlenci ME, et l Response to liposoml doxorubicin nd clinicl outcome of HIV-1-infected ptients with Kposi s srcom receiving highly ctive ntiretrovirl therpy. HIV Clin Trils, 2: Osob D, Northfelt DW, Budd DW, et l Effect of tretment on helth-relted qulity of life in cquired immunodeficiency syndrome (AIDS)-relted Kposi s srcom: A rndomized tril of pegylted liposoml doxorubicin versus doxorubicin, bleomycin, nd vincristine. Cncer Invest, 19: Peters BS, Beck EJ, Colemn DG, et l Chnging disese ptterns in ptients with AIDS in referrl centre in the United Kingdom: The chnging fce of AIDS. BMJ, 302: Simpson JK, Miller RF, Spittle MF Liposoml doxorubicin for tretment of AIDS-relted Kposi s srcom. Clin Oncol (R Coll Rdiol), 5: Stewrt S, Jblonowski H, Goebel FD, et l Rndomized comprtive tril of pegylted liposoml doxorubicin versus bleomycin nd vincristine in the tretment of AIDS-relted Kposi s srcom. Interntionl Pegylted Liposoml Doxorubicin Study Group. J Clin Oncol, 16: Sturzl M, Zietz C, Eisenburg B, et l Liposoml doxorubicin in the tretment of AIDS-ssocited Kposi s srcom: Clinicl, histologicl nd cell biologicl evlution. Res Virol, 145: Vil DM, Amnte MA, Colbern GT, et l Pegylted liposoml doxorubicin: Proof of principle using preclinicl niml models nd phrmcokinetic studies. Semin Oncol, 31(Suppl 13): Vogel J, Hinrichs SH, Reynolds RK, et l The HIV tt gene induces derml lesions resembling Kposi s srcom in trnsgenic mice. Nture, 335: Wgner D, Kern WV, Kern P Liposoml doxorubicin in AIDS-relted Kposi s srcom: Long-term experiences. Clin Investig, 72: Wng CY, Schroeter AL, Su WP Acquired immunodeficiency syndrome- relted Kposi s srcom. Myo Clin Proc, 70: Interntionl Journl of Nnomedicine 2007:2(3)

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell

More information

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground

More information

CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer

CheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn

More information

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess

More information

Supplementary Online Content

Supplementary Online Content Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern

More information

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5

Introduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5 Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,

More information

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT

SYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of

More information

Gemmis Injection 38 mg/ml

Gemmis Injection 38 mg/ml Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine

More information

Sponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)

Sponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept) These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*

See 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use GEMZAR sfely nd effectively. See full prescribing informtion for GEMZAR. GEMZAR (gemcitbine for injection)

More information

The RUTHERFORD-2 trial in heterozygous FH: Results and implications

The RUTHERFORD-2 trial in heterozygous FH: Results and implications The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of

More information

EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1

EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 Swine Dy 2001 Contents EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1 C. W. Hstd, S. S. Dritz 2, J. L. Nelssen, M. D. Tokch, nd R. D. Goodbnd Summry Two trils were

More information

IMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC

IMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,

More information

Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data

Emerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic

More information

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,

More information

Management of Relapsed/Refractory Follicular Lymphoma

Management of Relapsed/Refractory Follicular Lymphoma April 2018 Volume 16, Issue 4, Supplement 10 Mngement of Relpsed/Refrctory Folliculr Lymphom n How I Tret Relpsed/Refrctory Folliculr Lymphom: An Expert Perspective n Highlights from: The 2017 Americn

More information

Abstract. Background. Aim. Patients and Methods. Patients. Study Design

Abstract. Background. Aim. Patients and Methods. Patients. Study Design Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.

More information

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 : PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged

More information

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc)

Efficacy of Sonidegib in Patients With Metastatic BCC (mbcc) AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,

More information

University of Texas Health Science Center, San Antonio, San Antonio, Texas, USA

University of Texas Health Science Center, San Antonio, San Antonio, Texas, USA Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University

More information

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer

Clinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini

More information

key words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous

key words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M

More information

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4 F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND

More information

Y. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3

Y. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3 Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed

More information

Revised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4)

Revised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4) HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------ WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively.

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),

More information

See 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*

See 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS* HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Gemzr sfely nd effectively. See full prescriing informtion for Gemzr. GEMZAR (gemcitine for injection),

More information

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.

More information

Mecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert:

Mecadox. Improves pig performance in a wide range of health and growing conditions. (Carbadox) Talk With a Phibro Expert: SWINE (Crbdox) Improves pig performnce in wide rnge of helth nd growing conditions The Advntge Over the yers, medicted feed dditive hs proven to be cost-effective mngement tool for improving pig performnce

More information

Summary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV)

Summary. Effect evaluation of the Rehabilitation of Drug-Addicted Offenders Act (SOV) Summry Effect evlution of the Rehbilittion of Drug-Addicted Offenders Act (SOV) The Rehbilittion of Drug-Addicted Offenders Act (SOV) ws lunched on April first 2001. This lw permitted the compulsory plcement

More information

The potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens

The potential future of targeted radionuclide therapy: implications for occupational exposure? P. Covens The potentil future of trgeted rdionuclide therpy: implictions for occuptionl exposure? Introduction: Trgeted Rdionuclide Therpy (TRT) Systemic tretment Molecule lbelled with rdionuclide delivers toxic

More information

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population

Opioid Use and Survival at the End of Life: A Survey of a Hospice Population 532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),

More information

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II Assessment of Depression in Multiple Sclerosis Vlidity of Including Somtic Items on the Beck Depression Inventory II Peggy Crwford, PhD; Noh J. Webster, MA Signs nd symptoms of multiple sclerosis (MS)

More information

Comparison of three simple methods for the

Comparison of three simple methods for the J. clin. Pth. (1967), 2, 5 Comprison of three simple methods for the ssessment of 'free' thyroid hormone T. M. D. GIMLETTE1 From the Rdio-Isotope Lbortory, St. Thoms's Hospitl, London SYNOPSIS A dilysis

More information

Original Article. Breast Care 2016;11: DOI: /

Original Article. Breast Care 2016;11: DOI: / Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest

More information

XII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV

XII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV XII. HIV/AIDS Knowledge bout HIV Trnsmission nd Misconceptions bout HIV One of the most importnt prerequisites for reducing the rte of HIV infection is ccurte knowledge of how HIV is trnsmitted nd strtegies

More information

Invasive Pneumococcal Disease Quarterly Report. July September 2017

Invasive Pneumococcal Disease Quarterly Report. July September 2017 Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report

More information

Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy

Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy Comprtive Sfety of Filgrstim versus Srgrmostim in Ptients Receiving Myelosuppressive Chemotherpy Gry Milkovich, B.S., Ronld J. Moleski, Phrm.D., John F. Reitn, Phrm.D., Dvid M. Dunning, M.D., Gene A. Gibson,

More information

WSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265;

WSU Tree Fruit Research and Extension Center, Wenatchee (509) ext. 265; FINAL REPORT WTFRC Project # AH-1-5 WSU Project # 13C-355-3 Project title: PI: Orgniztion: Coopertors: of Sunburn in Apples with RAYNOX Lrry Schrder, Horticulturist WSU Tree Fruit Reserch nd Extension

More information

DOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION

DOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed disodium)

More information

Using Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids

Using Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress

More information

In the treatment of cardiovascular disease (CVD), national

In the treatment of cardiovascular disease (CVD), national n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese

More information

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit Bright Futures Medicl Reference Tle 2 to 5 Dy (First Week) Visit Universl Action Metolic nd Verify documenttion of neworn metolic screening results, pproprite rescreening, nd needed follow-up. Document

More information

XALKORI (crizotinib) Is Available Through Specialty Pharmacies

XALKORI (crizotinib) Is Available Through Specialty Pharmacies XALKORI (crizotinib) Is Avilble Through Specilty Phrmcies Specilty Phrmcy Ordering Process The Provider s Office Submits XALKORI prescriptions to the specilty phrmcy vi: Phone Fx Internet Submits ny supporting

More information

Results. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77)

Results. Table 1: Demographic and Baseline Characteristics, Open-Label Safety Population Prior Double-Blind OC/APAP ER (n=77) Open-Lbel Extension of Rndomized, Double-Blind, Plcebo-Controlled, Phse 3 Study of the Sfety nd Anlgesic Efficcy of MNK-795 Oxycodone/Acetminophen Extended-Relese (OC/APAP ER) Tblets in n Acute Pin Model

More information

Immune-Mediated Adverse Reactions Management Guide

Immune-Mediated Adverse Reactions Management Guide Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt

More information

The Acute Time Course of Concurrent Activation Potentiation

The Acute Time Course of Concurrent Activation Potentiation Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette

More information

First-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)

First-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC) YOUR LIFE. First-line nd Mintennce Tretment with ALIMTA therpy for dvnced nonsqumous non-smll cell lung cncer (NSCLC) ALIMTA is pproved by the FDA in combintion with cispltin (nother chemotherpy drug)

More information

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu

More information

THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS

THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS THE EVALUATION OF DEHULLED CANOLA MEAL IN THE DIETS OF GROWING AND FINISHING PIGS John F. Ptience nd Doug Gillis SUMMARY

More information

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson

More information

Lung cancer is the most common cause of cancer deaths in

Lung cancer is the most common cause of cancer deaths in Originl Article A Phse I/II Study of Bortezomib in Combintion with Pclitxel, Crbopltin, nd Concurrent Thorcic Rdition Therpy for Non Smll-Cell Lung Cncer North Centrl Cncer Tretment Group (NCCTG)-N0321

More information

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years) Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments

More information

R Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1

R Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1 Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity

More information

Olanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study

Olanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne

More information

ClinicalTrials.gov Identifier: NCT

ClinicalTrials.gov Identifier: NCT Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni,

More information

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ZYPREXA sfely nd effectively. See full prescribing informtion for ZYPREXA. ZYPREXA (olnzpine) Tblet

More information

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population

Clinical statistics analysis on the characteristics of pneumoconiosis of Chinese miner population Originl Article Clinicl sttistics nlysis on the chrcteristics of pneumoconiosis of Chinese miner popultion Mei-Fng Wng 1 *, Run-Ze Li 2 *, Ying Li 2, Xue-Qin Cheng 1, Jun Yng 1, Wen Chen 3, Xing-Xing Fn

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS* 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use BASAGLAR sfely nd effectively. See full prescribing informtion for BASAGLAR BASAGLAR (insulin glrgine

More information

Reference Slide Deck. Abstract 553 Abstract 554 Abstract 560

Reference Slide Deck. Abstract 553 Abstract 554 Abstract 560 Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch

More information

Clinical Study. Oncology 2006;71:32 39 DOI: /

Clinical Study. Oncology 2006;71:32 39 DOI: / Oncology Clinicl Study Oncology 2006;71:32 39 DOI: 10.1159/000100447 Received: My 29, 2006 Accepted fter revision: December 9, 2006 Published online: Mrch 5, 2007 Efficcy of Consolidtion High-Dose Chemotherpy

More information

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding

More information

Presented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE

Presented at the 75 th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017 METHODS INTRODUCTION OBJECTIVE Seven-Yer Interim Results from the ESPRIT 10-Yer Postmrketing Surveillnce Registry of Adlimumb for Moderte to Severe Psorisis Frncisco Kerdel, 1 Aln Menter, 2 Jshin J. Wu, 3 Mreike Bereswill, 4 Dilek Arikn,

More information

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic

Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of

More information

YERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011

YERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use

More information

Geographical influence on digit ratio (2D:4D): a case study of Andoni and Ikwerre ethnic groups in Niger delta, Nigeria.

Geographical influence on digit ratio (2D:4D): a case study of Andoni and Ikwerre ethnic groups in Niger delta, Nigeria. Journl of Applied Biosciences 27: 1736-1741 ISSN 1997 5902 Geogrphicl influence on digit rtio (2D:4D): cse study of Andoni nd Ikwerre ethnic groups in Niger delt, Nigeri. Gwunirem, Isrel U 1 nd Ihemelndu,

More information

308 nm excimer lamp in combination with topical tacrolimus: A retrospective study of its efficacy and safety in childhood vitiligo

308 nm excimer lamp in combination with topical tacrolimus: A retrospective study of its efficacy and safety in childhood vitiligo ORIGINAL ARTICLE 308 nm excimer lmp in comintion with topicl tcrolimus: A retrospective study of its efficcy nd sfety in childhood vitiligo BS Chndrshekr, N Shoh, P Deprtment of Dermtology, Cutis, Acdemy

More information

1 Indications and Usage

1 Indications and Usage HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ERBITUX sfely nd effectively. See full prescriing informtion for ERBITUX. ERBITUX (cetuxim) injection,

More information

Radiation therapy (RT) for cancer that involves the thorax

Radiation therapy (RT) for cancer that involves the thorax Originl Article Prospective Explortory Anlysis of Crdic Biomrkers nd Electrocrdiogrm Abnormlities in Ptients Receiving Thorcic Rdition Therpy with High-Dose Hert Exposure Dniel R. Gomez, MD,* Syed Wmique

More information

HERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998

HERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. HERCEPTIN (trstuzum) Intrvenous Infusion

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Prentl doi:.8/nture57 Figure S HPMECs LM Cells Cell lines VEGF (ng/ml) Prentl 7. +/-. LM 7. +/-.99 LM 7. +/-.99 Fold COX induction 5 VEGF: - + + + Bevcizum: - - 5 (µg/ml) Reltive MMP LM mock COX MMP LM+

More information

Rheumatoid-susceptible alleles of HLA-DRB 1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists

Rheumatoid-susceptible alleles of HLA-DRB 1 are genetically recessive to non-susceptible alleles in the progression of bone destruction in the wrists Annls of the Rheumtic Diseses 1994; 53: 587-592 587 Deprtment of Orthopedic Surgery, Knsi Medicl University, Otokoym Hospitl, Kyoto, Jpn Y Tod Y Mori Deprtment of Orthopedic Surgery, Knsi Medicl University,

More information

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:

Original Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract: Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute

More information

Symptom Management and Supportive Care

Symptom Management and Supportive Care This mteril is protected y U.S. Copyright lw. Unuthorized reproduction is prohiited. For reprints contct: Reprints@AlphMedPress.com Symptom Mngement nd Supportive Cre Erly Intervention with Epoetin Alf

More information

PRACTICE GUIDELINE SERIES

PRACTICE GUIDELINE SERIES PRACTICE GUIDELINE SERIES 131 I Tositumom in lymphom M.C. Cheung MD,* J.A. McEchern MD,* A.E. Hynes,* R.M. Meyer MD,* K. Imrie md* nd the Memers of the Hemtology Disese Site Group # of Cncer Cre Ontrio

More information

Antiviral Therapy 2015; 20: (doi: /IMP2825)

Antiviral Therapy 2015; 20: (doi: /IMP2825) Antivirl Therpy 2015; 20:209 216 (doi: 10.3851/IMP2825) Originl rticle Cost-effectiveness of boceprevir co-dministrtion versus pegylted interferon-2b nd ribvirin only for ptients with heptitis C genotype

More information

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use

More information

Simulating the Effect of Exercise on Urea Clearance in

Simulating the Effect of Exercise on Urea Clearance in BRIEF COMMUNICATION Simulting the Effect of Exercise on Ure Clernce in Hemodily si s STEPHEN W. SMYE,* ELIZABETH J. LINDLEY,* nd ERIC J. WILLt Deprtments of *Medicl Physics nd Renl Medicine, St. Jmes s

More information

Introduction to Study Designs II

Introduction to Study Designs II Introdution to Study Designs II Commonly used study designs in publi helth & epidemiologi reserh Benjmin Rihrd H. Muthmbi, DrPH, MPH Stte HIV Epidemiologist HIV Epidemiology Investigtion Setion PA Deprtment

More information

CheckMate-142 Study Design

CheckMate-142 Study Design Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr

More information

Single-Molecule Studies of Unlabelled Full-Length p53 Protein Binding to DNA

Single-Molecule Studies of Unlabelled Full-Length p53 Protein Binding to DNA Single-Molecule Studies of Unlbelled Full-Length p53 Protein Binding to DNA Philipp Nuttll, 1 Kidn Lee, 2 Pietro Ciccrell, 3 Mrco Crminti, 3 Giorgio Ferrri, 3 Ki- Bum Kim, 2 Tim Albrecht 1* 1 Imperil College

More information

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Herceptin sfely nd effectively. See full prescriing informtion for Herceptin. HERCEPTIN (trstuzum)

More information

TR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:

TR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary: (2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron

More information

INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable

INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable (pliperidone plmitte) extended-relese injectble suspension, for intrmusculr use HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively.

More information

Adverse Events Grading Card

Adverse Events Grading Card Adverse Events Grding Crd Common Terminology Criteri for Adverse Events* In clinicl studies, 2 of the most common dverse events reported with ALAVEN were peripherl neuropthy nd neutropeni. 1 With this

More information

Lung cancer is the leading cause of cancer death worldwide, EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas

Lung cancer is the leading cause of cancer death worldwide, EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas Originl Article EGFR Muttion nd Brin Metstsis in Pulmonry Adenocrcinoms Dong-Yeop Shin, MD,* Im Il N, MD,* Cheol Hyeon Kim, MD, PhD, Sunhoo Prk, MD, PhD, HeeJong Bek, MD, PhD, nd Sung Hyun Yng, MD, PhD*

More information

For Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

For Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) For Adults With Previously Treted Advnced Non-Smll Cell Lung Cncer (NSCLC) individuls depicted re models used for illustrtive purposes only. It cn be overwhelming to lern tht your previously treted dvnced

More information

LATE RESULTS OF TRANSFER OF THE TIBIAL TUBERCLE FOR RECURRENT DISLOCATION OF THE PATELLA1

LATE RESULTS OF TRANSFER OF THE TIBIAL TUBERCLE FOR RECURRENT DISLOCATION OF THE PATELLA1 LATE RESULTS OF TRANSFER OF THE TIBIAL TUBERCLE FOR RECURRENT DISLOCATION OF THE PATELLA1 W. G. J. HAMPSON nd P. HILL, BRISTOL, ENGLAND The uthors wished to determine the lte results of the Huser opertion,

More information

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project Kidney Interntionl, Vol. 64 (2003), pp. 1120 1124 Anemi in peditric hemodilysis ptients: Results from the 2001 ESRD Clinicl Performnce Mesures Project DIANE L. FRANKENFIELD, ALICA M. NEU, BRADLEY A. WARADY,

More information

Journal of Hainan Medical University.

Journal of Hainan Medical University. 132 Journl of Hinn Medicl University 2017; 23(11): 132-136 Journl of Hinn Medicl University http://www.hnykdxxb.com Assessment of the efficcy nd sfety of bronchil rtery perfusion chemotherpy combined with

More information

P (RCC) was first done in the late 1930s and reported in

P (RCC) was first done in the late 1930s and reported in Pulmonry Resection of Metsttic Renl Cell Crcinom Robert J. Cerfolio, MD, Mrk S. Allen, MD, Clude Deschmps, MD, Richrd C. Dly, MD, Steven L. Wllrichs, BS, Victor F. Trstek, MD, nd Peter C. Pirolero, MD

More information

Trends in Mortality From COPD Among Adults in the United States

Trends in Mortality From COPD Among Adults in the United States [ Originl Reserch COPD ] Trends in Mortlity From COPD Among Adults in the United Sttes Erl S. Ford, MD, MPH BACKGROUND: COPD imposes lrge public helth burden interntionlly nd in the United Sttes. The objective

More information

Reports of cases of AIDS, HIV infection, and HIV/AIDS 1

Reports of cases of AIDS, HIV infection, and HIV/AIDS 1 Reports of cses of AIDS, HIV infection, nd HIV/AIDS 1 The HIV/AIDS Surveillnce Report is published nnully by the Division of HIV/AIDS Prevention Surveillnce nd Epidemiology, Ntionl Center for HIV, STD,

More information

EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE

EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE Swine Dy 22 Contents EFFECTS OF AN ACUTE ENTERIC DISEASE CHALLENGE ON IGF-1 AND IGFBP-3 GENE EXPRESSION IN PORCINE SKELETAL MUSCLE B. J. Johnson, J. P. Kyser, J. D. Dunn, A. T. Wyln, S. S. Dritz 1, J.

More information

Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia

Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia 284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,

More information

Potential for Interactions Between Dietary Supplements and Prescription Medications a

Potential for Interactions Between Dietary Supplements and Prescription Medications a CLINICAL RESEARCH STUDY Potentil for Interctions Between Dietry Supplements nd Prescription Medictions Amit Sood, MD, MSc, Rich Sood, MD, b Frncis J. Brinker, ND, Rvneet Mnn, MBBS, c Lur L. Loehrer, Dietlind

More information

Age related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer

Age related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,

More information

One of the most important biological mechanisms of

One of the most important biological mechanisms of Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,

More information

Optimisation of diets for Atlantic cod (Gadus morhua) broodstock: effect of arachidonic acid on egg & larval quality

Optimisation of diets for Atlantic cod (Gadus morhua) broodstock: effect of arachidonic acid on egg & larval quality Optimistion of diets for Atlntic cod (Gdus morhu) roodstock: effect of rchidonic cid on egg & lrvl qulity Dr Gordon Bell, Ms. An Blnco, Dr Bill Roy, Dr Derek Roertson, Dr Jim Henderson nd Mr Richrd Prickett,

More information